COVID-19 in Pediatric Populations
Overview
Affiliations
The COVID-19 pandemic reshaped the landscape of respiratory viral illnesses, causing common viruses to fade as SARS-CoV-2 took precedence. By 2023, more than 96% of the children in the United States were estimated to have been infected with SARS-CoV-2, with certain genetic predispositions and underlying health conditions posing risk factors for severe disease in children. Children, in general though, exhibit immunity advantages, protecting against aspects of the SARS-CoV-2 infection known to drive increased severity in older adults. Post-COVID-19 complications such as multisystem inflammatory syndrome in children and long COVID have emerged, underscoring the importance of vaccination. Here, we highlight the risks of severe pediatric COVID-19, age-specific immunoprotection, comparisons of SARS-CoV-2 with other respiratory viruses, and factors contributing to post-COVID-19 complications in children.
Immune molecule links COVID‑19 with severe inflammatory disorder in children.
Nature. 2025; .
PMID: 40075196 DOI: 10.1038/d41586-025-00735-7.
TGFβ links EBV to multisystem inflammatory syndrome in children.
Goetzke C, Massoud M, Frischbutter S, Guerra G, Ferreira-Gomes M, Heinrich F Nature. 2025; .
PMID: 40074901 DOI: 10.1038/s41586-025-08697-6.
Liu V, Godfrey M, Dunn M, Fowler R, Guthrie L, Dredge D Front Pediatr. 2025; 12():1484941.
PMID: 39764158 PMC: 11700732. DOI: 10.3389/fped.2024.1484941.